Seres Therapeutics (MCRB) Retained Earnings (2014 - 2026)

Seres Therapeutics has reported Retained Earnings for 13 years, with the latest figure at -$992.3 million in Q1 2026.

• Quarterly Retained Earnings fell 4.96% year-over-year to -$992.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$992.3 million (down 4.96% YoY) and the FY2025 annual result came in at -$972.4 million, up 0.58% from the prior year.
• Retained Earnings slipped to -$992.3 million in Q1 2026 per MCRB's latest filing, from -$972.4 million in the prior quarter.
• Over five years, Retained Earnings peaked at $2000.0 in Q1 2023 and troughed at -$992.3 million in Q1 2026.
• A 5-year average of -$739.0 million and a median of -$945.4 million in 2025 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2022 and 2023: Retained Earnings slumped 7233872.73% in 2022, then surged 100.93% in 2023.
• Over 5 years, Retained Earnings stood at -$864.5 million in 2022, then dropped by 13.15% to -$978.2 million in 2023, then rose by 0.01% to -$978.1 million in 2024, then climbed by 0.58% to -$972.4 million in 2025, then slipped by 2.05% to -$992.3 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$992.3 million, -$972.4 million, and -$957.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.